Summary & Overview
HCPCS P9035: Platelets, Pheresis, Leukocytes Reduced, Each Unit
HCPCS Level II code P9035 denotes a single unit of plateletpheresis product that has undergone leukocyte reduction. This code captures a commonly used blood product preparation intended to reduce leukocyte-associated transfusion risks and is integral to hospital transfusion services and apheresis centers nationwide. Recognition of P9035 matters for standardized billing across payers, inventory management in blood banks, and reimbursement for the technical processes involved in producing leukocyte-reduced platelet units.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how this product is characterized clinically, typical sites of service, and relevant billing context. The publication outlines common modifiers associated with HCPCS billing for blood products (listed elsewhere), benchmarks for unit-level billing where available, and policy or coverage considerations that commonly affect payment and documentation for plateletpheresis products.
The report provides clinical context for when leukocyte-reduced plateletpheresis units are used, operational implications for transfusion services, and the billing elements that influence claim adjudication. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code P9035 represents platelets collected by pheresis with leukocyte reduction, billed per unit. The service involves collection and processing of a single unit of plateletpheresis product in which leukocytes are reduced to lower the risk of febrile nonhemolytic transfusion reactions and alloimmunization.
Service type: Blood product collection and processing (therapeutic/collection service for transfusion supply).
Typical site of service: Hospital blood bank, transfusion service, or licensed apheresis/collection center where blood products are prepared for transfusion.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with refractory thrombocytopenia secondary to myelodysplastic syndrome presents for outpatient therapeutic platelet transfusion. The transfusion service orders apheresis platelets that are leukocyte‑reduced to minimize febrile nonhemolytic transfusion reactions and alloimmunization. The patient arrives to the hospital transfusion suite or ambulatory infusion center with recent complete blood count showing a platelet count of 12,000/µL and mucocutaneous bleeding. Vital signs are stable. A transfusion consent is verified, baseline vitals recorded, and blood bank confirms blood product compatibility and availability of apheresis, leukocyte‑reduced platelet unit(s). The unit labeled and documented as P9035 is transported from the blood bank to the procedure area. A registered nurse with transfusion training performs pre‑transfusion safety checks, establishes peripheral IV access, and initiates infusion per facility transfusion protocols while monitoring for transfusion reactions. Post‑transfusion platelet count is obtained within 1–4 hours to assess increment and document clinical effect. Typical sites of service include the hospital inpatient unit, hospital outpatient infusion center, ambulatory surgical center with transfusion capability, or a dedicated blood bank/transfusion service area. This service is commonly provided by hematology/oncology teams, hospital medicine, or transfusion medicine specialists coordinating with blood bank personnel.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |